The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...

The company says preclinical trials demonstrate its signature molecule can help prevent cell damage that can lead to ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to ...

Just as he did with the development of the Covid-19 vaccines, Donald Trump likes to take credit for victories he wasn’t ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Rising demand for precision medicine & groundbreaking innovations in RNA sequencing drive growth in oncology, drug discovery, & personalized therapies.

COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.

Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking ...

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

DelveInsight’s, “Squamous Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ ...